Physicians' Academy for Cardiovascular Education

Heart failure & Diabetes: Time for a more unified approach

Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017

Video navigation menu

  • Diabetes is an important comorbidity in HF. 00:19
  • The results of the EMPA-REG OUTCOME trial suggest that empagliflozin may prevent the development of HF 01:44
  • Considering that HF was not an inclusion criterium in EMPA-REG OUTCOME trial, what can we say about the type of HF that some developed?  05:21
  • What do the ESC guidelines say about management of HF with diabetes? 07:21
  • Outstanding questions on the use of SGLT2 inhibitors for treatment of HF 08:04

Educational information

The educational objectives of this symposium were to:

Faculty

Stefan D. Anker, MD is Professor of (Tissue)Homeostasis in Cardiology & Metabolism, Charité, Berlin, Germany

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

This symposium was supported by an unrestricted educational grant provided by Boehringer-Ingelheim/Lilly

View Biography and Keyslides